原始研究:在α-1抗素缺乏症中遗传和代谢因素的扩大
Christina Schrader1, Malin Fromme1, Paul Ellis2
1Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany.
Hepatology (Baltimore, Md.)
|March 11, 2026
概括
肥胖和糖尿病加剧了阿尔法-1抗素缺乏症 (AATD) 患者的肝病. 这些代谢因素增加了肝脏终点风险,突出了它们在AATD管理中的重要性.
科学领域:
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
- 肝病学 肝病学是一种肝病学.
- 肺部病理学 肺部病理学
背景情况:
- 阿尔法-1抗素缺乏症 (AATD),包括严重的 (Pi*ZZ) 和异合的 (Pi*MZ) 基因型,与肝脏和肺部死亡率的增加有关.
- AATD的临床表现非常可变,这表明其他促成因素的影响.
研究的目的:
- 研究肥胖和糖尿病对有或没有AATD的个体的影响.
- 评估代谢条件如何改变AATD的表型,特别是关于肝脏和肺部的结果.
主要方法:
- 对比来自英国生物库的1678名Pi*ZZ成年人与国际数据的前性队列,与16768名Pi*MZ和415208名非AATD个人进行比较.
- 利用多变量调整和倾向得分匹配来分析基线特征和纵向后续数据.
- 使用转氨酶,APRI评分和肝硬度测量 (LSM) 评估肝脏健康;在平均4.2年内跟踪肝脏和肺部终点.
主要成果:
- 患有糖尿病的Pi*ZZ个体表现出显著更高的转氨酶和晚期肝纤维化标志物 (aOR 5.7/4.3).
- 超重和肥胖与Pi*ZZ成年人中转氨基酶和纤维化标志物升高有关 (aOR 1.5-4.1).
- 糖尿病和肥胖症增加了Pi*ZZ参与者的肝脏终点风险 (aHR 6.03/3.38),而超重显示肺部终点风险降低 (aHR 0.45).
结论:
- 在AATD中的遗传倾向与肥胖和糖尿病等代谢风险因素有显著的相互作用.
- 这些发现强调了代谢健康在AATD患者管理和疾病进展中的关键作用.
- 有证据支持将代谢风险因素评估纳入AATD患者的临床策略.
更多相关视频
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
55
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
55
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
83
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
01:23Cystic Fibrosis: Pathogenesis
994
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
994
01:29Pharmacogenomics: Identification of New Drug Targets
61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61